Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jonas

Showing results (541-550 of 557) with videos related to

Pageof 56
Sort By:
Hepatology (Baltimore, Md.)|June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA StudyMaureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Gastroenterology|November 2, 2010
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis CKathleen B Schwarz, Regino P Gonzalez-Peralta, Karen F Murray, et al.
Hepatology Communications|November 10, 2018
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4Daniel H Leung, Stefan Wirth, Betty B Yao, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11Karen F Murray, William F Balistreri, Sanjay Bansal, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA StudyMaureen M Jonas, Susan Rhee, Deirdre A Kelly, et al.
Nature|March 31, 2017
Using coherence to enhance function in chemical and biophysical systemsGregory D Scholes, Graham R Fleming, Lin X Chen, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 5, 2026
Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancerG Naidu, D P Moore, T Reljic, et al.
Hepatology (Baltimore, Md.)|June 22, 2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionPhilip Rosenthal, Kathleen B Schwarz, Regino P Gonzalez-Peralta, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 22, 2024
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infectionMaureen M Jonas, Rene Romero, Philip Rosenthal, et al.
Pageof 56

Showing results (541-550 of 557) with videos related to

Sort By:
Pageof 56
Hepatology (Baltimore, Md.)|June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA StudyMaureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Gastroenterology|November 2, 2010
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis CKathleen B Schwarz, Regino P Gonzalez-Peralta, Karen F Murray, et al.
Hepatology Communications|November 10, 2018
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4Daniel H Leung, Stefan Wirth, Betty B Yao, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11Karen F Murray, William F Balistreri, Sanjay Bansal, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA StudyMaureen M Jonas, Susan Rhee, Deirdre A Kelly, et al.
Nature|March 31, 2017
Using coherence to enhance function in chemical and biophysical systemsGregory D Scholes, Graham R Fleming, Lin X Chen, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 5, 2026
Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancerG Naidu, D P Moore, T Reljic, et al.
Hepatology (Baltimore, Md.)|June 22, 2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionPhilip Rosenthal, Kathleen B Schwarz, Regino P Gonzalez-Peralta, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 22, 2024
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infectionMaureen M Jonas, Rene Romero, Philip Rosenthal, et al.
Pageof 56